S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Vertex Pharmaceuticals (VRTX) Stock Forecast, Price & News

+3.14 (+1.23%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.55 million shs
Average Volume
1.73 million shs
Market Capitalization
$66.14 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Vertex Pharmaceuticals logo

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$7.57 billion
Cash Flow
$12.94 per share
Book Value
$42.65 per share


Net Income
$2.34 billion
Pretax Margin




Free Float
Market Cap
$66.14 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.08 out of 5 stars

Medical Sector

502nd out of 1,420 stocks

Pharmaceutical Preparations Industry

225th out of 679 stocks

Analyst Opinion: 2.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view top-rated stocks.

Are investors shorting Vertex Pharmaceuticals?

Vertex Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 3,410,000 shares, a decrease of 16.8% from the April 15th total of 4,100,000 shares. Based on an average trading volume of 1,630,000 shares, the short-interest ratio is currently 2.1 days. Approximately 1.4% of the shares of the company are sold short.
View Vertex Pharmaceuticals' Short Interest

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Vertex Pharmaceuticals

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its earnings results on Thursday, May, 5th. The pharmaceutical company reported $3.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.17 by $0.01. The pharmaceutical company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.07 billion. Vertex Pharmaceuticals had a net margin of 30.84% and a trailing twelve-month return on equity of 32.24%. The company's quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.54 EPS.
View Vertex Pharmaceuticals' earnings history

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $8.40 billion-$8.60 billion, compared to the consensus revenue estimate of $8.58 billion.

What price target have analysts set for VRTX?

18 analysts have issued 12 month price objectives for Vertex Pharmaceuticals' stock. Their forecasts range from $175.00 to $350.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $272.95 in the next twelve months. This suggests a possible upside of 5.6% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the following people:
  • Dr. Jeffrey Marc Leiden M.D., Ph.D., Exec. Chairman (Age 66, Pay $281.98k)
  • Dr. Reshma Kewalramani FASN, M.D., CEO, Pres & Director (Age 49, Pay $4.27M)
  • Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 54, Pay $1.85M) (LinkedIn Profile)
  • Mr. Stuart A. Arbuckle B.Sc., Exec. VP & COO (Age 56, Pay $2.56M)
  • Dr. Ourania Tatsis Ph.D., Exec. VP and Chief Regulatory & Quality Officer (Age 51, Pay $1.33M)
  • Ms. Kristen C. Ambrose, Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services (Age 45) (LinkedIn Profile)
  • Dr. David M. Altshuler M.D., Ph.D., Exec. VP of Global Research & Chief Scientific Officer (Age 57)
  • Mr. Mike Tirozzi, SVP and Chief Information & Data Officer
  • Mr. Michael Partridge, Sr. VP of Investor Relations
  • Mr. Damian W. Wilmot Esq., Sr. VP, Chief Risk and Compliance Officer (Age 46)
What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Salesforce (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.36%), Vanguard Group Inc. (8.00%), Capital World Investors (4.95%), State Street Corp (4.71%), Wellington Management Group LLP (3.15%) and Loomis Sayles & Co. L P (2.50%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals

Which institutional investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, ARK Investment Management LLC, Jennison Associates LLC, Bellevue Group AG, KBC Group NV, State Street Corp, Loomis Sayles & Co. L P, and Clal Insurance Enterprises Holdings Ltd. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Joy Liu, Kristen Ambrose, Margaret G Mcglynn, Ourania Tatsis, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Capital World Investors, Lord Abbett & CO. LLC, Aaron Wealth Advisors LLC, Assenagon Asset Management S.A., American Century Companies Inc., Mayflower Financial Advisors LLC, and Victory Capital Management Inc.. Company insiders that have bought Vertex Pharmaceuticals stock in the last two years include Bruce I Sachs, and Reshma Kewalramani.
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $258.59.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $66.14 billion and generates $7.57 billion in revenue each year. The pharmaceutical company earns $2.34 billion in net income (profit) each year or $9.50 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,900 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc. a Delaware corporation, Torreyana Insurance Company Inc. a Vermont corporation, Vectrus, Vertex Farmaceutica do Brasil LTDA a Brazilian company, Vertex Holdings Inc. a Delaware corporation, Vertex Pharmaceuticals (Australia) Pty. Ltd. an Australian company, Vertex Pharmaceuticals (Belgium) BV, Vertex Pharmaceuticals (CH) GmbH a Swiss company, Vertex Pharmaceuticals (Canada) Incorporated a Canadian company, Vertex Pharmaceuticals (Cayman 509) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman 765) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman 787) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman III) Limited a Cayman Islands company, Vertex Pharmaceuticals (Cayman) Limited a Cayman Islands company, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC a Delaware limited liability company, Vertex Pharmaceuticals (Distribution) Incorporated a Delaware corporation, Vertex Pharmaceuticals (Europe) Limited a United Kingdom company, Vertex Pharmaceuticals (France) SAS a French company, Vertex Pharmaceuticals (Germany) GmbH a German company, Vertex Pharmaceuticals (Ireland) Limited an Irish company, Vertex Pharmaceuticals (Italy) S.r.L. an Italian company, Vertex Pharmaceuticals (Netherlands) B.V. a Dutch company, Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal) Unipessoal Lda. a Portuguese company, Vertex Pharmaceuticals (Puerto Rico) LLC a Delaware limited liability company, Vertex Pharmaceuticals (San Diego) LLC a Delaware limited liability company, Vertex Pharmaceuticals (Singapore) Pte. Ltd. a Singapore company, Vertex Pharmaceuticals (Spain) S.L. a Spanish company, Vertex Pharmaceuticals (Sweden) AB a Sweden company, Vertex Pharmaceuticals (U.K.) Limited a United Kingdom company, Vertex Pharmaceuticals GmbH an Austrian company, Vertex Pharmaceuticals Single Member Societe Anonyme a Greek company, and Vertex Securities Corporation a Massachusetts corporation.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100, via email at [email protected], or via fax at 617-576-2109.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.